Found: 81
Select item for more details and to access through your institution.
Can Women With HER2-Positive Metastatic Breast Cancer Be Cured?
- Published in:
- 2021
- By:
- Publication type:
- journal article
Assessing the Effect of Lifetime Contralateral Breast Cancer Risk on the Selection of Contralateral Prophylactic Mastectomy for Unilateral Breast Cancer.
- Published in:
- 2018
- By:
- Publication type:
- journal article
A Phase II Trial of Docetaxel With Bevacizumab as First-line Therapy for HER2-Negative Metastatic Breast Cancer (TORI B01).
- Published in:
- Clinical Breast Cancer, 2010, v. 10, n. 4, p. 307, doi. 10.3816/CBC.2010.n.040
- By:
- Publication type:
- Article
Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer.
- Published in:
- Breast Cancer Research & Treatment, 2022, v. 195, n. 2, p. 127, doi. 10.1007/s10549-022-06602-7
- By:
- Publication type:
- Article
Systematic review and meta-analysis of febrile neutropenia risk with TCH(P) in HER2-positive breast cancer.
- Published in:
- Breast Cancer Research & Treatment, 2021, v. 190, n. 3, p. 357, doi. 10.1007/s10549-021-06387-1
- By:
- Publication type:
- Article
Neratinib + capecitabine sustains health-related quality of life in patients with HER2-positive metastatic breast cancer and ≥ 2 prior HER2-directed regimens.
- Published in:
- Breast Cancer Research & Treatment, 2021, v. 188, n. 2, p. 449, doi. 10.1007/s10549-021-06217-4
- By:
- Publication type:
- Article
Baseline characteristics and first-line treatment patterns in patients with HER2-positive metastatic breast cancer in the SystHERs registry.
- Published in:
- Breast Cancer Research & Treatment, 2021, v. 188, n. 1, p. 179, doi. 10.1007/s10549-021-06103-z
- By:
- Publication type:
- Article
Mechanistic basis for PI3K inhibitor antitumor activity and adverse reactions in advanced breast cancer.
- Published in:
- Breast Cancer Research & Treatment, 2020, v. 181, n. 2, p. 233, doi. 10.1007/s10549-020-05618-1
- By:
- Publication type:
- Article
Clinical features of pseudocirrhosis in metastatic breast cancer.
- Published in:
- Breast Cancer Research & Treatment, 2019, v. 177, n. 2, p. 409, doi. 10.1007/s10549-019-05311-y
- By:
- Publication type:
- Article
Profiling and targeting HER2-positive breast cancer using trastuzumab emtansine.
- Published in:
- Pharmacogenomics & Personalized Medicine, 2014, v. 7, p. 329, doi. 10.2147/PGPM.S47524
- By:
- Publication type:
- Article
Pembrolizumab-induced nephrotoxicity in a patient with breast cancer.
- Published in:
- Therapeutic Advances in Medical Oncology, 2024, p. 1, doi. 10.1177/17588359241248362
- By:
- Publication type:
- Article
Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib + endocrine therapy versus endocrine therapy alone in patients with HR+/HER2− early breast cancer.
- Published in:
- Therapeutic Advances in Medical Oncology, 2023, v. 15, p. 1, doi. 10.1177/17588359231178125
- By:
- Publication type:
- Article
Chemotherapy regimen choice and patient outcomes in early-stage triple-negative breast cancer: a retrospective analysis.
- Published in:
- Therapeutic Advances in Medical Oncology, 2022, p. 1, doi. 10.1177/17588359221085556
- By:
- Publication type:
- Article
Increasing Appropriate BRCA1/2 Mutation Testing: The Role of Family History Documentation and Genetic Counseling in a Multidisciplinary Clinic.
- Published in:
- Annals of Surgical Oncology: An Oncology Journal for Surgeons, 2016, v. 23, p. 634, doi. 10.1245/s10434-016-5545-0
- By:
- Publication type:
- Article
Antibody-drug conjugates: an emerging modality for the treatment of cancer.
- Published in:
- Annals of the New York Academy of Sciences, 2014, v. 1321, n. 1, p. 41, doi. 10.1111/nyas.12499
- By:
- Publication type:
- Article
A phase 1, first-in-human study of AMG 900, an orally administered pan-Aurora kinase inhibitor, in adult patients with advanced solid tumors.
- Published in:
- Investigational New Drugs, 2018, v. 36, n. 6, p. 1060, doi. 10.1007/s10637-018-0625-6
- By:
- Publication type:
- Article
What Does the Future Hold for PI3K/AKT/ mTOR Inhibitors in Breast Cancer?
- Published in:
- Journal of OncoPathology, 2013, v. 1, n. 4, p. 73, doi. 10.13032/tjop.2052-5931.100069
- By:
- Publication type:
- Article
Advances in Targeted Therapies for Triple-Negative Breast Cancer.
- Published in:
- Drugs, 2019, v. 79, n. 11, p. 1217, doi. 10.1007/s40265-019-01155-4
- By:
- Publication type:
- Article
Role of lapatinib alone or in combination in the treatment of HER2-positive breast cancer.
- Published in:
- Breast Cancer: Targets & Therapy, 2012, v. 4, p. 35, doi. 10.2147/BCTT.S29996
- By:
- Publication type:
- Article
New Treatment Paradigms in the Management of Metastatic Breast Cancer.
- Published in:
- Journal of Managed Care Medicine, 2014, v. 17, n. 1, p. 52
- By:
- Publication type:
- Article
AMEERA-5: a randomized, double-blind phase 3 study of amcenestrant plus palbociclib versus letrozole plus palbociclib for previously untreated ER+/HER2– advanced breast cancer.
- Published in:
- Therapeutic Advances in Medical Oncology, 2022, p. 1, doi. 10.1177/17588359221083956
- By:
- Publication type:
- Article
Oncotype DX Recurrence Score in premenopausal women.
- Published in:
- Therapeutic Advances in Medical Oncology, 2022, p. 1, doi. 10.1177/17588359221081077
- By:
- Publication type:
- Article
Correlation between work productivity loss and EORTC QLQ-C30 and -BR23 domains from the MONALEESA-7 trial of premenopausal women with HR+/HER2− advanced breast cancer.
- Published in:
- Therapeutic Advances in Medical Oncology, 2022, p. 1, doi. 10.1177/17588359221081203
- By:
- Publication type:
- Article
Phase II randomized trial of a non-steroidal mouth wash for prevention and treatment of stomatitis in women with hormone receptor positive breast cancer treated with everolimus.
- Published in:
- Therapeutic Advances in Medical Oncology, 2020, p. 1, doi. 10.1177/1758835920967259
- By:
- Publication type:
- Article
Tumor biomarkers and efficacy in patients treated with trastuzumab emtansine + pertuzumab versus standard of care in HER2-positive early breast cancer: an open-label, phase III study (KRISTINE).
- Published in:
- Breast Cancer Research, 2023, v. 25, n. 1, p. 1, doi. 10.1186/s13058-022-01587-z
- By:
- Publication type:
- Article
Targeting activated PI3K/mTOR signaling overcomes acquired resistance to CDK4/6-based therapies in preclinical models of hormone receptor-positive breast cancer.
- Published in:
- 2020
- By:
- Publication type:
- journal article
HERMIONE: a randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician's choice plus trastuzumab in patients with previously treated, anthracycline-naïve, HER2-positive, locally advanced/metastatic breast cancer.
- Published in:
- 2016
- By:
- Publication type:
- journal article
OUR KEY OPINION LEADERS HAVE BEEN BUSY! TAKE A LOOK TO SEE WHAT HAVE BEEN UP TO.
- Published in:
- Oncology (08909091), 2023, v. 37, n. 3, p. 95
- By:
- Publication type:
- Article
Experts Discuss Third-line Treatment Options for HER2-Positive Advanced Breast Cancer.
- Published in:
- Oncology (08909091), 2021, v. 35, n. 10, p. 682
- By:
- Publication type:
- Article
HER2-Positive Breast Cancer: Special Challenges and Expert Insight.
- Published in:
- Oncology (08909091), 2021, v. 35, n. 6, p. 363
- By:
- Publication type:
- Article
Relapsed/Refractory HER2+ Metastatic Breast Cancer.
- Published in:
- Oncology (08909091), 2021, v. 35, n. 4, p. 215
- By:
- Publication type:
- Article
Advancing the Paradigm of Breast Cancer Therapies by Critically Gauging Success Across Histologies.
- Published in:
- Oncology (08909091), 2021, v. 35, n. 4, p. 162
- By:
- Publication type:
- Article
Cardiotoxicity of Targeted Agents in Oncology: A Medical Oncology Perspective.
- Published in:
- 2014
- By:
- Publication type:
- Journal Article
Acute and Chronic Effects of Adjuvant Therapy on Inflammatory Markers in Breast Cancer Patients.
- Published in:
- JNCI Cancer Spectrum, 2022, v. 6, n. 4, p. 1, doi. 10.1093/jncics/pkac052
- By:
- Publication type:
- Article
Outcomes in Clinically Relevant Patient Subgroups From the EMBRACA Study: Talazoparib vs Physician's Choice Standard-of-Care Chemotherapy.
- Published in:
- JNCI Cancer Spectrum, 2020, v. 4, n. 1, p. N.PAG, doi. 10.1093/jncics/pkz085
- By:
- Publication type:
- Article
Acute health-related quality of life outcomes and systemic inflammatory markers following contemporary breast cancer surgery.
- Published in:
- NPJ Breast Cancer, 2022, v. 8, n. 1, p. 1, doi. 10.1038/s41523-022-00456-4
- By:
- Publication type:
- Article
Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancer—phase 3 ASCENT study subanalysis.
- Published in:
- NPJ Breast Cancer, 2022, v. 8, n. 1, p. 1, doi. 10.1038/s41523-022-00439-5
- By:
- Publication type:
- Article
A careful reassessment of anthracycline use in curable breast cancer.
- Published in:
- NPJ Breast Cancer, 2021, v. 7, n. 1, p. 1, doi. 10.1038/s41523-021-00342-5
- By:
- Publication type:
- Article
NatHER: protocol for systematic evaluation of trends in survival among patients with HER2-positive advanced breast cancer.
- Published in:
- Systematic Reviews, 2015, v. 4, n. 1, p. 1, doi. 10.1186/s13643-015-0118-z
- By:
- Publication type:
- Article
Event-Free Survival in Patients with Early HER2-Positive Breast Cancer with a Pathological Complete Response after HER2-Targeted Therapy: A Pooled Analysis.
- Published in:
- Cancers, 2022, v. 14, n. 20, p. 5051, doi. 10.3390/cancers14205051
- By:
- Publication type:
- Article
A Novel Thienopyrimidine Analog, TPH104, Mediates Immunogenic Cell Death in Triple-Negative Breast Cancer Cells.
- Published in:
- Cancers, 2021, v. 13, n. 8, p. 1954, doi. 10.3390/cancers13081954
- By:
- Publication type:
- Article
Expression of Phosphorylated BRD4 Is Markedly Associated with the Activation Status of the PP2A Pathway and Shows a Strong Prognostic Value in Triple Negative Breast Cancer Patients.
- Published in:
- Cancers, 2021, v. 13, n. 6, p. 1246, doi. 10.3390/cancers13061246
- By:
- Publication type:
- Article
Efficacy and safety of everolimus in combination with trastuzumab and paclitaxel in Asian patients with HER2+ advanced breast cancer in BOLERO-1.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Clinical evaluation of BCL-2/X<sub>L</sub> levels pre- and post- HER2-targeted therapy.
- Published in:
- PLoS ONE, 2021, v. 16, n. 5, p. 1, doi. 10.1371/journal.pone.0251163
- By:
- Publication type:
- Article
Predictors associated with MRI surveillance screening in women with a personal history of unilateral breast cancer but without a genetic predisposition for future contralateral breast cancer.
- Published in:
- Breast Cancer Research & Treatment, 2017, v. 166, n. 1, p. 145, doi. 10.1007/s10549-017-4392-4
- By:
- Publication type:
- Article
In vitro activity of the mTOR inhibitor everolimus, in a large panel of breast cancer cell lines and analysis for predictors of response.
- Published in:
- Breast Cancer Research & Treatment, 2015, v. 149, n. 3, p. 669, doi. 10.1007/s10549-015-3282-x
- By:
- Publication type:
- Article
Use of the metastatic breast cancer progression (MBC-P) questionnaire to assess the value of progression-free survival for women with metastatic breast cancer.
- Published in:
- Breast Cancer Research & Treatment, 2013, v. 142, n. 3, p. 603, doi. 10.1007/s10549-013-2734-4
- By:
- Publication type:
- Article
A phase 2 study of everolimus combined with trastuzumab and paclitaxel in patients with HER2-overexpressing advanced breast cancer that progressed during prior trastuzumab and taxane therapy.
- Published in:
- Breast Cancer Research & Treatment, 2013, v. 141, n. 3, p. 437, doi. 10.1007/s10549-013-2689-5
- By:
- Publication type:
- Article
Phase Ib/II single-arm trial evaluating the combination of everolimus, lapatinib and capecitabine for the treatment of HER2-positive breast cancer with brain metastases (TRIO-US B-09).
- Published in:
- Therapeutic Advances in Medical Oncology, 2018, v. 10, n. 1, p. 1, doi. 10.1177/1758835918807339
- By:
- Publication type:
- Article
Ado-trastuzumab emtansine (T-DM1) in human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer: latest evidence and clinical potential.
- Published in:
- Therapeutic Advances in Medical Oncology, 2014, v. 6, n. 5, p. 202, doi. 10.1177/1758834014539183
- By:
- Publication type:
- Article